Biomab EGFR contains nimotuzumab, a monoclonal antibody that targets the epidermal growth factor receptor, commonly known as EGFR. It is used primarily in the treatment of various EGFR-expressing cancers, including head and neck cancers, gliomas, and certain types of lung cancers. Nimotuzumab offers a targeted approach by acting directly on cancer cells that overexpress EGFR, helping to slow down their growth and spread. Its ability to selectively bind to tumor cells with minimal effect on normal tissues makes it a more tolerable therapy for many patients.

Mechanism of Action

Nimotuzumab is a humanized IgG1 monoclonal antibody that binds specifically to the extracellular domain of the EGFR protein on the surface of cancer cells. EGFR plays a crucial role in cell proliferation, survival, and angiogenesis. In many cancers, EGFR is overactive, leading to uncontrolled cell growth. By binding to EGFR, nimotuzumab blocks its activation and downstream signaling pathways, thereby inhibiting tumor growth, angiogenesis, and promoting apoptosis or programmed cell death. Unlike some other EGFR-targeting therapies, nimotuzumab tends to spare healthy tissues due to its intermediate affinity for EGFR, reducing severe toxicity.

Uses

Biomab EGFR is commonly used in combination with radiation or chemotherapy for the following conditions:

• Head and neck squamous cell carcinoma, especially unresectable or locally advanced tumors

• High-grade glioma or glioblastoma, particularly in pediatric and adult patients

• Non-small cell lung cancer expressing EGFR

• Investigational uses in esophageal, colorectal, and pancreatic cancers

  Adverse Effects

  Common Side Effects

  • Fatigue or general weakness

  • Mild skin rash, especially around the face or upper chest

  • Fever or chills during infusion

  • Nausea or vomiting, typically mild and manageable

  • Headache or mild flu-like symptoms